Scaleup programmes

Back to programmes

Programme

IP Group [2022]

Finance and Risk Capital

Impact for scaleups

82

UK companies backed

34%

Follow-on investments

88%

Investments outside of London

62

Growth-stage investments

Key sectors

Building & Construction Manufacturing / Advanced Manufacturing Creative, digital, film, games & media Professional services Defence & security Technology & Communications Engineering / Advanced Engineering Transport & Logistics Environmental Science & Technology Farming, fisheries & forestry Finance Food & drink Healthcare Impact ventures / Social Impact Life Sciences & Biotech

Now 21 years old, IP Group is an FTSE-250 listed IP commercialisation company which has helped to develop more than 400 companies. With a focus on life sciences, deeptech and cleantech, it invests in university spin-outs at seed, venture and growth stages and assists them with the commercialisation of their new products and services, with technology transfer, IP licensing and protection. It continues to invest in portfolio companies as they scale. 

The firm has a long-term partnership model with UK universities and developed an approach to supporting businesses from “cradle to maturity,” including assistance with executive search and recruitment and raising growth stage capital from co-investors. It currently has partnerships with 17 UK universities, six US universities and nine universities in Australia and New Zealand. 

The company owns Parkwalk Advisors, an active EIS investor in university spin-outs of ‘hard science’ companies, and has stakes in Oxford Sciences Innovation and Cambridge Innovation Capital. Several of its portfolio companies have completed landmark corporate transactions with the highlight being Oxford Nanopore’s multi-billion-pound flotation. Other UK scaleups in its portfolio include Ultraleap, Crescendo Biologics, First Light Fusion and Istesso.

IP Group [2022] website